This clinical trial is focused on studying the long-term effects of a treatment for a condition called retinopathy of prematurity (ROP). ROP is an eye disease that affects premature babies, where abnormal blood vessels grow in the retina, the part of the eye that senses light. The treatment being studied involves a medication called aflibercept, which is marketed under the name Eylea. Eylea is a solution that is injected into the eye to help manage the condition.

The purpose of this study is to evaluate the long-term safety and visual outcomes of children who received this treatment in a previous study. Participants in this study will be monitored over several years to assess their vision and any potential side effects. The study will look at how well the children can see at different ages and whether they experience any eye-related or general health issues. It will also check for any structural changes in the eye, such as retinal detachment, which is when the retina pulls away from its normal position.

Throughout the study, researchers will also evaluate the children’s overall development using standardized tests. These tests will help determine if the treatment has any impact on their growth and learning abilities. The study aims to provide valuable information on the long-term effects of using Eylea for treating retinopathy of prematurity, helping to improve future care for children with this condition.